Search research articles
Contact Us
Filters
Showing results (161-170 of 215) with videos related to
Page
of 22
Sort By:
Cancers
|
June 2, 2021
Enhanced Efficacy of Aurora Kinase Inhibitors in G2/M Checkpoint Deficient <i>TP53</i> Mutant Uterine Carcinomas Is Linked to the Summation of LKB1-AKT-p53 Interactions
Katherine N Lynch, Joyce F Liu, Nikolas Kesten, et al.
Nature Communications
|
May 31, 2022
STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer
Qiwei Wang, Johann S Bergholz, Liya Ding, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 29, 2022
A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial Cancer
Panagiotis A Konstantinopoulos, Elizabeth K Lee, Niya Xiong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 15, 2019
The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition
Kalindi Parmar, Bose S Kochupurakkal, Jean-Bernard Lazaro, et al.
Nature Communications
|
March 27, 2026
Mirvetuximab soravtansine plus pembrolizumab in recurrent folate receptor alpha-positive uterine serous carcinoma: a phase II trial
Rebecca L Porter, Yinglu Zhou, Nebiyat Eskndir, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 14, 2019
Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial
Ursula A Matulonis, Lydia Walder, Trine J Nøttrup, et al.
Gynecologic Oncology
|
March 26, 2025
ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety
Ursula A Matulonis, Jørn Herrstedt, Amit Oza, et al.
Gynecologic Oncology Reports
|
April 18, 2022
A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma
Elizabeth H Stover, Niya Xiong, Andrea P Myers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 23, 2012
Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome
Zhigang C Wang, Nicolai Juul Birkbak, Aedín C Culhane, et al.
JCO Precision Oncology
|
April 10, 2025
Serial Circulating Tumor DNA Sequencing to Monitor Response and Define Acquired Resistance to Letrozole/Abemaciclib in Endometrial Cancer
Panagiotis A Konstantinopoulos, Mingyang Cai, Elizabeth K Lee, et al.
Page
of 22
Search research articles
Search
Showing results (161-170 of 215) with videos related to
Sort By:
Page
of 22
Cancers
|
June 2, 2021
Enhanced Efficacy of Aurora Kinase Inhibitors in G2/M Checkpoint Deficient <i>TP53</i> Mutant Uterine Carcinomas Is Linked to the Summation of LKB1-AKT-p53 Interactions
Katherine N Lynch, Joyce F Liu, Nikolas Kesten, et al.
Nature Communications
|
May 31, 2022
STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer
Qiwei Wang, Johann S Bergholz, Liya Ding, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 29, 2022
A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial Cancer
Panagiotis A Konstantinopoulos, Elizabeth K Lee, Niya Xiong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 15, 2019
The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition
Kalindi Parmar, Bose S Kochupurakkal, Jean-Bernard Lazaro, et al.
Nature Communications
|
March 27, 2026
Mirvetuximab soravtansine plus pembrolizumab in recurrent folate receptor alpha-positive uterine serous carcinoma: a phase II trial
Rebecca L Porter, Yinglu Zhou, Nebiyat Eskndir, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 14, 2019
Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial
Ursula A Matulonis, Lydia Walder, Trine J Nøttrup, et al.
Gynecologic Oncology
|
March 26, 2025
ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety
Ursula A Matulonis, Jørn Herrstedt, Amit Oza, et al.
Gynecologic Oncology Reports
|
April 18, 2022
A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma
Elizabeth H Stover, Niya Xiong, Andrea P Myers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 23, 2012
Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome
Zhigang C Wang, Nicolai Juul Birkbak, Aedín C Culhane, et al.
JCO Precision Oncology
|
April 10, 2025
Serial Circulating Tumor DNA Sequencing to Monitor Response and Define Acquired Resistance to Letrozole/Abemaciclib in Endometrial Cancer
Panagiotis A Konstantinopoulos, Mingyang Cai, Elizabeth K Lee, et al.
Page
of 22